Recombinant Biotinylated Human VSIG3 Protein, Fc, Avitag™, 25 µg

Background
VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.

Source
Recombinant Biotinylated Human VSIG3 protein, Fc,Avitag (VS3-H82F9) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Gly 241 (Accession # Q5DX21-1).
Predicted N-terminus: Leu 23

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 51.5 kDa. The protein migrates as 60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics"
Yuan, Chen, Jin et al
Comput Struct Biotechnol J (2024) 23, 1534-1546
(2) "VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy"
Shekari, Shanehbandi, Kazemi et al
Cancer Cell Int (2023) 23 (1), 265
(3) "Adenosine Methylation Level of miR-125a-5p Promotes Anti-PD-1 Therapy Escape through the Regulation of IGSF11/VSIG3 Expression"
Bougras-Cartron, Nadaradjane, Joalland et al
Cancers (Basel) (2023) 15 (12)
Showing 1-3 of 10 papers.